The Commission shall make public a report on the performance of pharmacovigilance tasks by the Agency on 2 January 2014 at the latest and subsequently every 3 years thereafter.
Art. 29 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…
Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 Novembe…14Law
1. Kromě požadavků na farmakovigilanci stanovených v článcích 21 až 29 nařízení (ES) č. 726/2004 žadatel v žádosti o registraci uvede předpokládaná opatření pro zajištění sledování účinnosti a nežádoucích …
Regulation (EC) No 219/2009 of the European Parliament and of the Council of 11 March 20…Lawamends
Opinion of Advocate General Saugmandsgaard Øe delivered on 25 July 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and OthersDecision
Furthermore, Articles 21 to 29 of that regulation provide for a system of pharmacovigilance for the medicinal products authorised at EU level.
25 Jul 2018 · 62017CC0029
Changed on 2 Jul 2012
The Commission may adopt any amendment which may be necessary to update the provisions of this Chapter in order to take account of scientific and technical progress. Those measures, designed to amend non-essential elements of this regulation, shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 87(2a)shall make public a report on the performance of pharmacovigilance tasks by the Agency on 2 January 2014 at the latest and subsequently every 3 years thereafter.
- 2 Jul 2012 – todayin force
- 20 Apr 2009 – 2 Jul 2012earlier wording
- 31 Mar 2004 – 20 Apr 2009earlier wording